Although nicotinamide, a class III HDAC inhibitor, was shown to improve cognitive function in Alzheimer’s disease (AD) mouse models, a phase 2a proof-of-concept clinical trial indicated that further development of nicotinamide as a potential intervention for AD must address challenges related to its limited bioavailability and rapid methylation metabolism [233]. Here, HDAC9 is linked to Alzheimer disease.